19.25亿,艾伯维引进CD3/BCMA/CD38管线

药渡
13 Jul

▎追溯2025 年 7 月 10 日, 艾伯维 (NYSE: ABBV) 和纽约Ichnos Glenmark Innovation, Inc. (IGI)的全资子公司 IGI Therapeutics SA宣布了一项独家许可协议,针对 IGI 的主要研究资产 ISB 2001,该资产使用 IGI 专有的 BEAT 蛋白质平台开发,用于治疗肿瘤和自身免疫性疾病。ISB 2001 是同类首创的三...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10